within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG10_Inebilizumab;

model Inebilizumab
  extends Pharmacolibrary.Drugs.ATC.L.L04AG10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L04AG10</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Inebilizumab is a humanized monoclonal antibody directed against CD19, a protein expressed on B cells. It is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. It acts by depleting B cells involved in autoimmune pathophysiology.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported for adult NMOSD patients receiving intravenous inebilizumab in clinical trials.</p><h4>References</h4><ol><li><p>Agius, MA, et al., &amp; Flor, A (2019). Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. <i>Multiple sclerosis (Houndmills, Basingstoke, England)</i> 25(2) 235–245. DOI:<a href=&quot;https://doi.org/10.1177/1352458517740641&quot;>10.1177/1352458517740641</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29143550/&quot;>https://pubmed.ncbi.nlm.nih.gov/29143550</a></p></li><li><p>Yan, L, et al., &amp; Rees, WA (2022). Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders. <i>British journal of clinical pharmacology</i> 88(8) 3803–3812. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15332&quot;>10.1111/bcp.15332</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35332558/&quot;>https://pubmed.ncbi.nlm.nih.gov/35332558</a></p></li><li><p>Yan, L, et al., &amp; Rees, WA (2022). Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis. <i>Clinical pharmacokinetics</i> 61(3) 387–400. DOI:<a href=&quot;https://doi.org/10.1007/s40262-021-01071-5&quot;>10.1007/s40262-021-01071-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34718986/&quot;>https://pubmed.ncbi.nlm.nih.gov/34718986</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Inebilizumab;
